Cataracts, dry eyes, glaucoma and other eye problems become more common with age. But these can be treated — and sometimes ...

Who wouldn’t love having long, fluttering, effortless lashes? Celebrities, artists, and influential people are seen sporting these eye accessories. It makes the eyes pop, something that is hard to ...

Frequency of Eye Diseases in Subjects Aged 40 and Over. Open Journal of Ophthalmology, 15, 11-17. doi: ...

The lower humidity associated with winter can dry out your skin and make your hair brittle if you’re not careful. Cold, dry ...

11, 2025 (GLOBE NEWSWIRE) -- The "Corneal Edema - Epidemiology Forecast - 2034" report has been added to ... diagnosis reinforce the need for heightened awareness and improved diagnostic methods to ...

Background/aims This study aimed to assess the efficacy and sterility of stored platelet-rich plasma (PRP) eye-drops for corneal epithelial wound healing compared with those of autologous serum (AS) ...

Susvimo is the first and only FDA-approved treatment shown to maintain vision in people with diabetic macular edema with fewer treatments based on its continuous delivery of a customized formulation ...

This issue was related to mild lenticular edema. Corneal recovery and full transparency were observed within the third post-operative month in all patients. No adverse events of any type were observed ...

Measurements were conducted between 9:00 and 10:00 AM to minimize the effects of diurnal variations and overnight corneal edema. Only images graded as “OK” in terms of quality were collected. Data ...

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened its label as a treatment for diabetic macular edema (DME), which is the ...

The US Food and Drug Administration (FDA) has approved ranibizumab injection) 100 mg/mL (Susvimo; Genentech) for the treatment of diabetic macular edema (DME). The company noted that Susvimo is the ...

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing sustained vision improvements with fewer treatments than standard eye ...